VOR
Vor Biopharma Inc. [VOR] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
VOR Stock Summary
Top VOR Correlated Resources
VOR
Top 10 Correlated ETFs
VOR
Top 10 Correlated Stocks
VOR
In the News
VOR Financial details
Company Rating
-
Market Cap
129.61M
Income
-115.87M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
168
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-1.38
Forward P/E
-
PEG
0.56
P/S
-
P/B
0.89
P/C
-
P/FCF
-1.63
Quick Ratio
10.4
Current Ratio
10.69
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.73
EPS next Y
-
EPS next Q
-
EPS this Y
-23.58%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-20.41%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-50%
ROE
-52%
ROC
-0.59%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.62-5.7
52W High
-86.11%
52W Low
-30.54%
RSI
41
Rel Volume
0.62
Avg Volume
315.34K
Volume
196.48K
Perf Week
11.4%
Perf Month
-22.83%
Perf Quarter
-4.43%
Perf Half Y
0.67%
-
-
-
-
Beta
-0.365
-
-
Volatility
0.02%, 0.11%
Prev Close
6.86%
Price
0.6946
Change
6.68%
Company Profile
- Volume Average 315.34K
- Market Capitalization 129.61M
- Employee 168
- CEO Dr. Robert Ang M.B.A., M.D., MBBS
- Headquarters Cambridge,MA,US
- IPO Date 2021-02-05
-
Website
https://www.vorbio.com 
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
